Research programme: eye disorders cell therapy - Celogos

Drug Profile

Research programme: eye disorders cell therapy - Celogos

Alternative Names: RCD-3

Latest Information Update: 24 Jul 2006

Price : $50

At a glance

  • Originator Celogos
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Blepharoptosis; Eye disorders

Most Recent Events

  • 24 Jul 2006 Preclinical trials in Blepharoptosis in France (Ophthalmic)
  • 24 Jul 2006 Preclinical trials in Eye disorders in France (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top